Business
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif., December 15, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in pati
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/63efce53eccbde2d5d8b1a729a1e0c48"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vCND3dUl7iBizcaCnZgFYQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/63efce53eccbde2d5d8b1a729a1e0c48","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/cCn2skJuBg4W.ydUGkntsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/63efce53eccbde2d5d8b1a729a1e0c48","width":1121,"height":442}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., December 15, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patients with Ataxia-Telangiectasia (A-T). The company expects to report topline results from this study in the middle of the first quarter of 2026.","length":661,"tagName":"p"},{"type":"text","content":"Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, "Completing our pivotal Phase 3 NEAT clinical trial marks a major milestone for Quince as we rapidly move toward reporting topline results in the middle of the first quarter of 2026. Conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration, the study was powered at approximately 90% for a treatment difference versus placebo associated with a statistically significant and clinically meaningful treatment difference in a previous trial. The study has been executed with low rates of discontinuations and missing visits – all of which we believe enhance our probability of success. In addition, an unblinded, independent data safety monitoring board has met three times during the course of the study with no safety concerns identified.","length":866,"tagName":"p"},{"type":"text...